What is XtalPi?
Founded in 2014, XtalPi operates at the vanguard of the digital health revolution, utilizing proprietary AI-driven platforms to predict the crystalline structures of drug candidates. This technological edge allows the firm to significantly reduce the time and cost associated with traditional laboratory experimentation. By partnering with major pharmaceutical entities, XtalPi facilitates the creation of robust intellectual property portfolios and accelerates the path to market for novel therapeutics. The company's market position is defined by its ability to bridge the gap between high-performance computing and complex molecular biology, effectively transforming the R&D landscape for global healthcare providers.
How much funding has XtalPi raised?
XtalPi has raised a total of $784.8M across 4 funding rounds:
Series A
$5M
Series C
$318.8M
Series B
$61M
Series D
$400M
Series A (2015): $5M with participation from Tencent
Series C (2020): $318.8M led by PICC Capital, SoftBank Vision Fund 2, and The Morningside Group
Series B (2021): $61M supported by Sequoia China, Tencent, GV, BGF, Yael Capital, and China Life Healthcare Fund
Series D (2021): $400M featuring HOPU Investment Management Co. and OrbiMed Healthcare Fund Management
Key Investors in XtalPi
Tencent
Tencent is a global technology company that develops digital platforms, software, and internet based services for consumers and businesses, with a strong focus on supporting innovation through a broad ecosystem of products.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
HOPU Investment Management Co.
HOPU Investment Management is a firm operating in the investment banking sector, providing strategic capital to support growth-stage enterprises.
What's next for XtalPi?
With the recent influx of capital, XtalPi is well-positioned to scale its computational infrastructure and expand its collaborative network within the global pharmaceutical industry. The firm is expected to prioritize the enhancement of its predictive algorithms, aiming to address more complex biological targets and further streamline the drug discovery pipeline. As the company matures, the focus will likely shift toward deepening its strategic alliances and potentially diversifying its therapeutic focus areas, ensuring that its AI-powered solutions remain the industry standard for efficiency and precision in drug development.
See full XtalPi company page
